Pzena Investment Management REGN trades
Richard Pzena
Richard Pzena Regeneron Pharmaceuticals Inc stake
total: 590
Trades details
- Total transactions:
- 9
- New positions:
- 2
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 4
- Held since:
- 2026 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q3
According to 2026 Q3 report, Richard Pzena holds 409 Regeneron Pharmaceuticals Inc (REGN) shares with a market value of roughly $310.13K accounting for 0.00% of the overall portfolio. To date, the estimated cost basis is nearly $758.27 for "buy" trades. Pzena Investment Management first purchased REGN in 2021 Q1, initially acquiring 1,255 shares. Richard Pzena later completely sold out the position and invested in Regeneron Pharmaceuticals Inc again in 2026 Q3. Since the initial investment in Regeneron Pharmaceuticals Inc (REGN), Pzena Investment Management has made 8 more transactions.
When did Richard Pzena buy Regeneron Pharmaceuticals Inc (REGN)?
Richard Pzena first invested in Regeneron Pharmaceuticals Inc (REGN) in 2021 Q1 at the reported quarter-end price of $473.31 per share.
What's the cost basis of Pzena Investment Management's REGN stake?
The estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) stake is around $758.27 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $758.27
Richard Pzena's historical trades in Regeneron Pharmaceuticals Inc
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q3
|
0.00%
|
409
|
$758.27
|
$310,132
|
new
|
+0%
|
|
2022 Q4
|
0.00%
|
0
|
$688.92
|
|
-100% (-794)
|
-0%
|
|
2022 Q3
|
0.00%
|
794
|
$688.92
|
$547,000
|
-29.04% (-325)
|
-0%
|
|
2022 Q2
|
0.00%
|
1,119
|
$590.71
|
$661,000
|
+21.10% (+195)
|
+0%
|
|
2022 Q1
|
0.00%
|
924
|
$698.05
|
$645,000
|
+2.21% (+20)
|
+0%
|
|
2021 Q4
|
0.00%
|
904
|
$631.64
|
$571,000
|
-7.47% (-73)
|
-0%
|
|
2021 Q3
|
0.00%
|
977
|
$604.91
|
$591,000
|
-12.30% (-137)
|
-0%
|
|
2021 Q2
|
0.00%
|
1,114
|
$558.35
|
$622,000
|
-11.24% (-141)
|
-0%
|
|
2021 Q1
|
0.00%
|
1,255
|
$473.31
|
$594,000
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.